Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02623582 · ClinicalTrials.gov registry record · Early Phase 1
CD123 Redirected Autologous T Cells for AML
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT02623582: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT02623582 is a Early Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 7 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02623582, a Early Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART123) in Acute Myeloid Leukemia (AML) subjects.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-11-18 |
| Phase | Early Phase 1 |
Why NCT02623582 stopped before completion
NCT02623582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT02623582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02623582 about?
NCT02623582 is a clinical study titled "CD123 Redirected Autologous T Cells for AML". Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART123) in Acute Myelo...
What is the current status of trial NCT02623582?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2015-12. Estimated completion is 2016-11-18.
What interventions are being tested in trial NCT02623582?
The interventions under investigation include: Cyclophosphamide (DRUG), Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT02623582?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02623582's enrollment target sits among peer trials
7 1825th of 2000 higher than 156 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia